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PGC-1 and SREBP1c and 1a in liver. PGC-1 coacti- particles. Several transcription factors in the sterol re-
vates the SREBP transcription factor family and stimu- sponsive element binding protein (SREBP) family have
lates lipogenic gene expression. Further, PGC-1 is been shown to be key regulators of the transcriptional
required for SREBP-mediated lipogenic gene expres- activation of lipogenic genes (Horton et al., 2002). All
sion. However, unlike SREBP itself, PGC-1 reduces SREBP isoforms are synthesized as precursor proteins
fat accumulation in the liver while greatly increasing in the endoplasmic reticulum membrane and undergo
circulating triglycerides and cholesterol in VLDL parti- two steps of proteolytic cleavage (Brown and Goldstein,
cles. The stimulation of lipoprotein transport upon 1997). This leads to release of the N-terminal active
PGC-1 expression is likely due to the simultaneous forms which subsequently translocate into nucleus and
coactivation of the liver X receptor, LXR, a nuclear stimulate the expression of target genes. SREBP1a and
hormone receptor with known roles in hepatic lipid 1c (also called ADD1) isoforms are derived from a single
transport. These data suggest a mechanism through gene by alternative usage of transcription start sites,
which dietary saturated fats can stimulate hyperlipid- resulting in two proteins with different amino termini
emia and atherogenesis. (Shimomura et al., 1997; Tontonoz et al., 1993; Yoko-
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abundant accumulation of triglycerides and cholesterol, glyceride synthesis (Figure 1A). Notably, mRNA levels
for many enzymes in the cholesterol synthesis path-suggestive of an imbalance between lipid synthesis and
secretion (Horton et al., 1998; Shimano et al., 1996, way, such asHMG-CoA reductase, phosphomevalonate
kinase, and lanosterol synthase, are significantly ele-1997). In contrast, hepatic lipogenesis in healthy animals
and humans is tightly coupled to lipoprotein secretion, vated in response to dietary saturated fats. Interestingly,
the activation of this hepatic lipogenic program is ac-and hepatic steatosis does not usually develop.
Transcription factors function via docking of coactiva- companied by increased expression of two potentially
important hepatic transcriptional regulators, SREBP1c,tor proteins, and the coactivators that function with the
SREBPs in hepatic lipogenesis are largely unexplored. a central regulator of lipogenic gene expression, and
PGC-1, a transcription coactivator in the PGC-1 familyPrevious studies have shown that the CBP/p300 coacti-
vators are able to bind to and coactivate the SREBPs (Figure 1A). The mRNA level of SREBP1c is elevated
more than 7-fold at day 1 of high-fat feeding, as deter-(Oliner et al., 1996), but the biological significance of
this interaction in the regulation of endogenous genes mined by quantitative real-time PCR analysis (Figure
1B). The expression of SREBP1a is also induced approx-remains unclear. Recent studies indicate that the PGC-1
family of coactivators is of particular importance in the imately 2-fold. In contrast, SREBP2 expression remains
unchanged. Unlike PGC-1, which is only slightly in-control of liver metabolism (Puigserver and Spiegelman,
2003). PGC-1 stimulates mitochondrial biogenesis and duced by the dietary switch, the expression of PGC-1
mRNA is stimulated more than 4-fold in response torespiration in multiple cell types and modulates bio-
logical programs normally associated with increased high-fat feeding, paralleling that of SREBP1c (Figure
1B). Several-fold induction ofmRNA for lipogenic genes,oxidativemetabolism, such as hepatic gluconeogenesis
(Herzig et al., 2001; Yoon et al., 2001) and myofiber such as fatty acid synthase (FAS) and HMG-CoA reduc-
tase, is also shown by real-time PCR analysis (Figuredetermination (Lin et al., 2002b). It does so by coactivat-
ing transcription factors in a tissue-specific manner, 1B and data not shown). The expression of PGC-1 is
not altered in skeletal muscle and white adipose tissuesuch as HNF4 and FOXO1 in the liver (Puigserver et al.,
2003; Yoonet al., 2001), and theMEF2 familymembers in under these conditions (data not shown). Dietary intake
of cholesterol has little effect on the expression of PGC-skeletal muscle (Lin et al., 2002b).
PGC-1 is a recently identified transcriptional coacti- 1 (Supplemental Figure S1A at http://http://www.cell.
com/cgi/content/full/120/2/261/DC1/). These results dem-vator closely related to PGC-1 whose biological activi-
ties are largely unknown (Kressler et al., 2002; Lin et al., onstrate that dietary saturated fats and cholesterol have
distinct effects on the expression of mRNA for the2002a). Although PGC-1 shares a similar tissue distri-
butionwith PGC-1, they aredifferentially regulateddur- SREBPs and PGC-1. This striking induction of the ge-
netic program of hepatic lipogenesis following acuteing development and in response to changes in nutri-
tional status (Kamei et al., 2003; Lin et al., 2002a, 2003). intakeof a high saturated fat diet has not beenpreviously
noted to our knowledge.Like PGC-1, PGC-1 strongly activates mitochondrial
biogenesis and cellular respiration in differentiatedmyo- Previous studies have demonstrated that fatty acids,
especially polyunsaturated species, suppress both thetubes and hepatocytes (Lin et al., 2003; St-Pierre et
al., 2003). In this report, we have found that PGC-1 is expression of SREBP1c and the generation of cleaved
nuclear isoforms (Hannah et al., 2001). To determinecoinduced with SREBP1c/1a in response to short-term
high-fat feedingofmice. PGC-1coactivates theSREBP whether dietary fats have a direct impact on PGC-1
expression, we treated primary hepatocytes with vari-and LXR families of transcription factors as it induces
a broad program of lipid metabolism, including de novo ous saturated, unsaturated, and trans fatty acids and
examined the levels of PGC-1 mRNA. While monoun-lipogenesis and lipoprotein secretion. Our studies reveal
a novel mechanism whereby consumption of saturated saturated (oleic acid, C18:1n-9) and polyunsaturated (lino-
leic acid, C18:2n-6; EPA, C20:5n-3; DHA, C22:6n-3; and ara-fats may alter hepatic lipid metabolism and lead to hy-
pertriglyceridemia and hypercholesterolemia. chidonic acid, C20:4n-6) slightly induce PGC-1
expression, saturated fatty acids of varying chain length
(C10:0 to C18:0) elevate PGC-1 mRNA levels much moreResults
strongly (Figure 1C). Strikingly, trans fatty acids such
as elaidic acid (trans-C18:1n-9) and trans-vaccenic acidStimulation of a Program of Hepatic Lipogenesis
(trans-C18:1n-7), abundantly present in hydrogenatedby High-Fat Feeding
vegetable oil and dairy products, respectively, also ro-Metabolic pathways leading to increased total and LDL
bustly induce the expression of PGC-1 (3.2-fold). Incholesterol from consumption of saturated and trans
contrast, fatty acid treatments have no effect on thefats are incompletely understood. To investigate this,
expression of PGC-1 mRNA under these conditions,we fed mice a diet rich in saturated fats but with little
except stearic acid (C18:0), which also induces PGC-1or no cholesterol (58% fat, mainly from hydrogenated
mRNA 2.2-fold (Figure 1C). These results indicate thatcoconut oil; D12331, Research Diets). We concentrated
certain fatty acids, especially saturated and trans spe-on early changes, as these diets are known to bring
cies, can stimulate PGC-1 expression in a cell-autono-about many chronic effects, such as insulin resistance
mous manner.andobesity, whichmay confound the studyof regulatory
events leading to hyperlipidemia. Clustering analysis of
Affymetrix arrays revealed that the expression of a large Coactivation of the SREBP Family of Transcription
Factors by PGC-1number of genes involved in de novo lipid synthesis are
strongly induced following this high-fat feeding, includ- Coinductionof PGC-1andSREBP1c in the liver of high-
fat-fed mice suggested that PGC-1 might modulateing those responsible for fatty acid, cholesterol, and tri-
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Figure 1. Induction of PGC-1 Expression by Dietary Intake of Saturated Fats
(A) Cluster analysis of liver gene expression in response to high-fat feeding. Dietary changes and transcriptional profile analysis were performed
as described in the Experimental Procedures. Shown are genes involved in hepatic lipogenesis that are induced more than 1.8-fold in response
to high-fat feeding. Note that SREBP1c and PGC-1 are included in this lipogenic cluster.
(B) Real-time PCR analysis of total liver RNA from mice fed a high-fat diet for 24 (hatched box) or 48 hr (filled box). Relative mRNA abundance
was calculated by normalization to the control chow values (open box). n  4; *: p  0.01.
(C) Regulation of PGC-1 expression by free fatty acids in cultured hepatocytes. Primary hepatocytes were treated with 400 M of various
fatty acids for 4 hr as described in the Experimental Procedures. Total RNA was extracted and analyzed by real-time PCR using primers
specific for PGC-1 (filled box) and PGC-1 (open box). *: p  0.01.
the transcriptional activity of SREBP1c. As expected, tectedwhen control IgGwas used in the immunoprecipi-
tations (Figure 2C). These results indicate that SREBP1cSREBP1c activates the FAS promoter (Joseph et al.,
2002; Magana andOsborne, 1996; Tontonoz et al., 1993) is able to directly recruit PGC-1 to the proximity of its
binding sites on the target promoters. In fact, theseby approximately 5-fold in transiently transfected H2.35
mouse hepatoma cells (Figure 2A). PGC-1 greatly aug- two proteins physically interact in cells as shown by
coimmunoprecipitation assays. SREBP1c is able to in-ments the transcriptional activity of SREBP1c on this
promoter, as shown by a 17-fold increase in the lucifer- teract with and precipitate PGC-1, but not PGC-1,
when these proteins are coexpressed in hepatoma cellsase activity compared to the basal levels. In contrast,
PGC-1 has minimal effect on the activity of SREBP1c. (Figure 2D). In order to identify domains of PGC-1 that
interact with SREBP1c, we utilized a fusion protein be-Mutation of the SREBP binding site on the promoter
completely abolishes its activation by both SREBP1c tween GST and the processed form of SREBP1c. Full-
length PGC-1 interacts well with SREBP1c (Figure 2E),alone and the combination of SREBP1c and PGC-1,
indicating that PGC-1 coactivates SREBP1c through and analysis of PGC-1mutants revealed that a domain
(amino acids 350–530) unique for PGC-1, but absentthe SRE on this promoter. PGC-1 also strongly in-
creases the activity of SREBP2 and SREBP1a in these in PGC-1, is required for interaction between SREBP1c
and PGC-1 (Figures 2E–2F). These data indicate thatcoactivation assays (Figure 2B and data not shown).
To determine whether PGC-1 is recruited to SREs PGC-1, but not PGC-1, coactivates the SREBP family
of transcription factors by direct physical association.present in the promoter/enhancer region of endogenous
SREBP target genes, we performed chromatin immuno-
precipitation (ChIP) assay. As shown in Figure 2C, PGC- Activation of Hepatic Lipogenesis
and Hyperlipidemia by PGC-11, but not PGC-1, is present in proximity to the SRE
on the FAS promoter. Interestingly, the recruitment of To examine the effects of PGC-1 on the expression of
endogenous lipogenic genes,we infused rats via tail veinPGC-1 to SREBP binding sites seems to depend on
their promoter context; PGC-1 is not recruited to the injections with recombinant adenoviruses expressing
-galactosidase (-gal), PGC-1, or PGC-1. AdenovirusSRE on the LDLR promoter. No PCR product was de-
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Figure 2. Coactivation of the SREBP Family of Transcription Factors by PGC-1
(A) H2.35 mouse hepatoma cells were transiently transfected with either the wild-type FAS promoter (FAS 700 luc) or the SRE mutant
(FAS 700 SRE luc) reporter constructs, in combination with SREBP1c in the presence or absence of the PGC-1.
(B) Transient transfection of FAS 700 luc reporter plasmid with SREBP2 in the presence or absence of the PGC-1.
(C) ChIP analysis on SREBP target genes. Hepatoma cells were infected with adenoviruses for 48 hr as indicated and harvested for ChIP
analysis with anti-Flag antibody or control IgG (bottom). The precipitated genomic fragments were amplified using primers flanking SREs on
the FAS and LDLR promoters or control GAPDH promoter. Genomic DNA from total chromatin lysates was included as an input control.
(D) Coimmunoprecipitation of PGC-1 and SREBP1c. Cultured 293 cells were transfected with plasmids as indicated. Total lysates from
transfected cells were subjected to immunoprecipitation using antibodies specific for SREBP1c. Both lysates and precipitates were analyzed
by immunoblotting with antibodies specific for SREBP1c or the Flag epitope tag. Arrows indicate the bands corresponding to Flag-PGC-1
(f-PGC-1), Flag-PGC-1 (f-PGC-1) and SREBP1c.
(E) Mapping of PGC-1 domains that interact with SREBP1c. Glutathione beads containing immobilized GST () or GST-SREBP1c () were
incubated with in vitro translated 35-S-labeled full-length PGC-1 or truncated PGC-1 mutants. Shown in the left are in vitro translated PGC-
1 mutants equivalent to 10% of input for the interaction assay. The numbers above the gel denote amino acid positions of the mutants.
Note that a domain between amino acids 350 and 530 of PGC-1 is necessary for binding to SREBP1c.
(F) Diagram of the structure of PGC-1 and PGC-1 showing a domain unique for PGC-1 that provides the docking site for SREBP1c.
almost exclusively transduces hepatocytes when intro- by real-time PCR revealed that in addition to modulating
HMG-CoA reductase, PGC-1 also increases mRNAduced through the tail vein. As expected, both PGC-1
and PGC-1 stimulate the expression of mitochondrial level of multiple enzymes in the cholesterol synthesis
pathway,while PGC-1 hasmuchweaker effects (Figuregenes such as cytochrome c, ATPase, and medium
chain acyl-CoA dehydrogenase (MCAD) when ectopi- 3B). In fact, many of these PGC-1 target genes are
also highly induced in response to high-fat feeding, sug-cally expressed in liver (Figure 3A). PGC-1 also power-
fully stimulates the expression of genes involved in lipid gesting that PGC-1maybeakey factor inmediating the
effects of dietary saturated fats on hepatic lipogenesissynthesis, such as FAS, SCD-1, HMG-CoA reductase,
DGAT, and GPAT, all of which are well-known SREBP including cholesterol biosynthesis. Surprisingly, the ex-
pression of LDLR, a classic SREBP target, is not ele-targets. In striking contrast, PGC-1 has little or noeffect
on the expression of these genes. The expression of vated by PGC-1 (Figure 3C). This induction of SREBP
target genes by PGC-1 does not appear to be duemicrosomal triglyceride transfer protein (MTTP), a gene
that regulates VLDL secretion and is mutated in familial to increased levels of SREBP transcription factors as
shown by mRNA and protein analysis (Figures 3B andabetalipoproteinemia (Sharp et al., 1993), is induced by
both PGC-1 and PGC-1. Gene expression analysis 3D). Rather, these results are consistent with the obser-
PGC-1 Links Dietary Fats and Hyperlipidemia
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Figure 3. Induction of mRNAs Encoding Enzymes in the Pathways of Fatty Acid and Cholesterol Biosynthesis by PGC-1.
(A) Hybridization analysis of total liver RNA from rats transduced with the control adenovirus (Ad--gal), Ad-PGC-1 or Ad-PGC-1. Probe
specific for ribosomal protein 36B4 was included as a loading control.
(B) Induction of hepatic mRNAs encoding enzymes in the cholesterol biosynthesis pathway by PGC-1 compared to the high-fat-fed mouse
liver. The expression levels for high-fat-fed mouse liver represent normalized values obtained from the Affymetrix arrays. The expression of
these genes in response to PGC-1s was determined by real-time PCR analysis of total RNA from rat liver transduced with adenoviral vectors
as indicated. Note that PGC-1 stimulates the expression of multiple enzymes involved in cholesterol biosynthesis, which are also induced
in response to high-fat feeding.
(C) Real-time PCR analysis of hepatic gene expression. Relative mRNA levels were obtained after normalization to 18S rRNA. Note that the
LDLR mRNA levels are not altered by PGC-1 expression. *: p  0.05.
(D) PGC-1 has no effects on the expression and processing of SREBP1c in rat liver. Shown are membrane and nuclear forms of rat
SREBP1c protein.
vation that PGC-1 coactivates SREBPs through direct caused profound plasma hypertriglyceridemia in rats,
with plasma triglyceride concentrations elevated morephysical association and augmentation of their tran-
scriptional activity. than 6-fold compared to control rats receiving Ad--gal
(Figure 4B). PGC-1also lowers liver triglyceride contentTransgenic expression of SREBP in mouse liver acti-
vates lipogenic gene expression, and lipids accumulate while slightly raising plasma triglyceride levels (Figures
4A and 4B). Analysis of plasma cholesterol indicatedin liver and fail to be exported to peripheral tissues
(Horton et al., 1998; Shimano et al., 1996, 1997). Indeed, that total cholesterol is increased approximately 55%
and 200% by PGC-1 and PGC-1, respectively (Figureplasma triglyceride levels are actually reduced in the
transgenic mice compared to wild-type controls, proba- 4C). The increase in plasma cholesterol is mainly a result
of accumulation of cholesterol in the VLDL fractions asbly due to increased LDLR levels in liver (Shimano et
al., 1997). Surprisingly, adenoviral-mediatedPGC-1ex- shown by FPLC analysis of lipoprotein profiles (Figure
4D). In fact, the level of triglycerides and cholesterolpression in liver lowers hepatic triglyceride content by
more than 50% in the high-fat-fed rats (Figure 4A). This in VLDL is increased 6.2- and 5.3-fold, respectively, in
response to PGC-1 compared to the -gal control (Fig-decrease in hepatic lipid storage may be explained by
an increase in lipid export as PGC-1 expression in liver ure 4E). In contrast, the level of HDL cholesterol is largely
Cell
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Figure 4. Induction of Hyperlipidemia by PGC-1
Rats were transduced via tail vein injection with adenoviruses as described in the Experimental Procedures.
(A–C) Liver triglycerides (A), plasma triglycerides (B), and total plasma cholesterol (C) in rats transduced with Ad--gal, Ad-PGC-1 or Ad-
PGC-1. (A) *: p  0.0003; (B) *: p  0.0001, **: p  0.007; (C) *: p  0.0004, **: p106.
(D) Analysis of lipoprotein profiles. Plasma from rats transduced with the control Ad--gal or Ad-PGC-1was fractionated by FPLC. Triglyceride
and cholesterol concentrations in each fraction were measured. Fractions corresponding to VLDL and HDL are indicated.
(E) Relative lipid content in VLDL fractions was calculated using areas under curve in (D). Shown are relative amounts of triglycerides (TG)
and cholesterol (Chol) in VLDL.
(F) Plasma triglyceride concentrations in rats transduced with adenoviral vectors expressing control -gal, PGC-1, dominant-negative
SREBP1c (DN), or the combination of PGC-1 and DN. *: p  0.0001 (PGC-1 versus -gal), **: p  0.02 (PGC-1 versus PGC-1DN).
unaffected. This is significant in light of the fact that of PGC-1 on lipogenic gene expression is mediated
through the SREBP family of transcription factors.VLDL cholesterol is the precursor of LDL cholesterol.
These data strongly suggest that although PGC-1 co-
activates the SREBPs and increases expression of the Modulation of the LXR Pathway by Both
PGC-1 and PGC-1lipogenic SREBP target genes, it also modulates lipid
transport pathways and alters the balance between he- The hypertriglyceridemia induced by PGC-1 is reminis-
cent of that caused in animals by activation of liver-Xpatic and plasma lipids.
To determinewhether SREBP is necessary formediat- receptor (LXR) with an agonist ligand (Grefhorst et al.,
2002; Schultz et al., 2000). LXR has also been showning the effects of PGC-1 on lipogenic gene expression,
we infused rats with Ad-PGC-1 in combination with a to play an important role in the regulation of lipid export
and reverse cholesterol transport in macrophageswell-characterized dominant-negativemutant of SREBP
(Foretz et al., 1999; Kim et al., 1995). While DN-SREBP (Chawla et al., 2001). To examine whether PGC-1 af-
fects transcriptional activity of LXR, we cotransfectedaalone has no effect on the levels of plasma triglycerides
compared to -gal controls, the DN mutant significantly reporter plasmid that containsmultimerized LXRbinding
sites (4	 LXRE-luc) with PGC-1andPGC-1. As showndiminishes hypertriglyceridemia caused by PGC-1
(Figure 4F). The induction of several lipogenic genes, in Figure 5A, PGC-1 strongly augments the activation
of reporter gene expression by LXR and RXR in asuch as FAS, SCD-1, and HMG-CoA reductase, are also
reduced when rats are transduced with both Ad-PGC- ligand-dependentmanner. Similarly, both PGC-1 coacti-
vators are able to augment the transcriptional activity1 and Ad-DN-SREBP (Supplemental Figure S1B on the
Cell website). Thus, a significant portion of the effects of LXR when assayed on this reporter construct (Sup-
PGC-1 Links Dietary Fats and Hyperlipidemia
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Figure 5. Coactivation of LXR by PGC-1 and -1
(A) H2.35 hepatoma cells were transiently transfected with 4	 LXRE-luc in combination with plasmids as indicated. Transfected cells were
treated with either vehicle DMSO (open box) or 10 M of the LXR agonist T0901317 (filled box) for 24 hr before luciferase assay.
(B) H2.35 hepatoma cells were transiently transfected with wild-type ABCA1 promoter reporter plasmid (ABCA1-luc) or a mutant lacking the
LXRE (ABCA1 LXRE-luc) in combination with plasmids as indicated.
(C) ChIP analysis on LXR target genes. H2.35 cells were infected with adenoviruses expressing GFP, flag-PGC-1, or flag-PGC-1. Cells were
treated with 10 M of T0901317 for 3 hr before harvesting. PCR was performed on input or precipitated DNA using primers as indicated.
(D) Induction of endogenous LXR target genes by PGC-1 and PGC-1. Real-time PCR analysis of total liver RNA isolated from rats transduced
with Ad--gal (open box), Ad-PGC-1 (hatched box) or Ad-PGC-1 (filled box).
(E) Interaction between LXR and the N termini of the PGC-1 proteins. In vitro translated LXR was incubated with GST or fusion proteins of
GST and the N termini of PGC-1s as indicated. The binding reactions were incubated in the presence () or absence () of 10 M T0901317.
Shown in the left is 10% of LXR input for the reactions.
plemental Figure S2A on the Cell website). Cotransfec- Sincemice deficient in the LXRs are known to express
SREBP1cvery poorly (Repaet al., 2000), it is not possibletion of PGC-1s increases the promoter activity of ATP
binding cassette transporter A1 (ABCA1) by approxi- to genetically determine the role of the LXRs in the PGC-
1 responses independent of SREBP1c. However, intro-mately 2-3 fold compared to LXR/RXR alone (Figure
5B). Mutation of the LXR binding site on the promoter duction of adenoviral PGC-1 into mice lacking both
LXR and LXR shows a complete loss of the hyperlipid-completely abolishes its regulation by LXR and PGC-
1s, indicating that LXR binding to its response element emic response shown in wild-type animals, consistent
with a role of the LXRs in this pathway (Supplementalon theABCA1 promoter is required formediating effects
of the PGC-1s. In fact, both PGC-1 and PGC-1 are Figure S2B on the Cell website).
recruited to the proximity of the LXREs present on the
promoters of CYP7a1 and ABCA1 and induce the ex- Requirement for PGC-1 in the Transcriptional
Activity of the SREBPspression of several endogenous LXR target genes (Fig-
ures 5C and 5D). Furthermore, these two coactivators The fact that PGC-1 is highly induced along with
SREBP1a/1c in response to high-fat feeding suggestsare able to directly bind LXR in an in vitro interaction
assay (Figure 5E). Deletion of a small region that con- that the concentration of PGC-1 in hepatocytes may
be a necessary and limiting factor for SREBP activity. Totains the conserved LXXLL motif (PGC-1 N350) re-
duced the binding between PGC-1 and LXR and com- examine this possibility, we constructed RNAi vectors
(RNAi #1 and #2) that specifically knock down PGC-1pletely abolished the effects of ligand.
Cell
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Figure 6. Requirement for PGC-1 in SREBP-Mediated Transcription
(A) Knockdown of PGC-1 protein levels by RNAi constructs. Cultured 293 cells were transiently transfected with PGC-1 expression plasmid
(f-PGC-1) in the presence of RNAi constructs or vector control. Transfected cells were harvested for immunoblotting using a monoclonal
antibody against the Flag epitope. Note that both RNAi constructs decrease PGC-1 protein levels compared to the vector control.
(B–E) Hepatoma cells were transiently transfected with FAS 700 luc (B and C), G6Pase 1200 luc (D) or 4	 LXRE-luc (E) in combination
with plasmids as indicated. For RNAi, either vector control or RNAi constructs directed toward PGC-1 were included in the transfection
experiments. Luciferase activity was measured 48 hr after transfection.
(F) Knockdown of endogenous PGC-1 protein by adenoviral expression of RNAi. H2.35 hepatoma cells were infected with a control RNAi
adenovirus or Ad-RNAi for two days. Total lysateswere prepared for immunoblotting analysis using polyclonal antibodies raised against PGC-1.
(G) A requirement of PGC-1 for the induction of endogenous SREBP target genes. H2.35 hepatoma cells were infected with Ad-GFP (filled
box) or Ad-RNAi (open box) for 48 hr and then infected with Ad-SREBP1c for 20 hr. Total RNA was isolated from infected cells and analyzed
by real-time PCR.
(H) H2.35 hepatoma cells were infected with Ad-GFP (filled box) or Ad-RNAi (open box) for 48 hr, and then treated with 10 M of T0901317
as indicated. Relative SREBP1c expression was determined by real-time PCR.
levels in cells. As shown in Figure 6A, both RNAi vectors Taken together, these data strongly suggest that PGC-
1 activity is required for the full transcriptional activitydirected toward PGC-1 reduce the protein level of
PGC-1 by 60%–90%when tested in transient transfec- of SREBP.
To determine whether PGC-1 is required for the ex-tion assays, compared to the control vector. We first
analyzed the effects of PGC-1 RNAi on SREBP tran- pression of endogenous SREBP1c targets, we used an
adenoviral RNAi vector (Ad-RNAi) toward PGC-1. Asscriptional activity in transient transfections. Activation
of the FAS promoter by SREBP1c is reduced more than shown in Figure 6F, treatment of hepatoma cells with
this Ad-RNAi reduces endogenous PGC-1 protein by60% by PGC-1 RNAi constructs compared to the con-
trol vector or a vector expressing random RNAi se- approximately 80%. No effect on PGC-1 expression
was detected (data not shown). As shown in Figure 6G,quence (Figure 6B). A very similar reduction of transcrip-
tional activity is also observed with these RNAis when SREBP1c expression in hepatoma cells strongly stimu-
lates mRNA abundance of several lipogenic genes suchcombined with SREBP2 and SREBP1a (Figure 6C and
data not shown). Importantly, these PGC-1 RNAi vec- as SCD-1 (3.5-fold), FAS (3.6-fold), and HMG-CoA re-
ductase (1.8-fold). The induction of all these genes intors have little or no effect on the regulation of G6Pase
promoter activity by PGC-1 and HNF4 (Figure 6D). response to SREBP1c, however, is greatly impaired in
the cells infected with Ad-RNAi compared to the controlThese RNAi vectors also do not alter LXR/RXR tran-
scriptional activity when assayed on a reporter con- GFP. Notably, while the induction of FAS and HMG-CoA
reductase is decreased more than 50%, the expressiontaining multimerized LXR responsive elements (Figure
6E), perhaps due to the presence of PGC-1 and/or of SCD-1 mRNA is reduced to near the basal level even
in the presence of SREBP1c. In contrast, the inductionother coactivator proteins for LXRs in hepatocytes.
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Figure 7. PGC-1 Is Required for Lipogenic Gene Expression and Lipid Homeostasis In Vivo
(A) Knockdown of endogenous PGC-1 in the livers from mice transduced with Ad-RNAi. Adenoviral transduction was performed as described
in the Experimental Procedures. Eighty micrograms of total liver lysates from mice receiving control or RNAi adenoviruses were subjected
to immunoblotting analysis using PGC-1 antibody.
(B) Hepatic gene expression in the mice transduced with control (filled box, n  5) or RNAi (open box, n  6) adenoviruses. *: p  0.03.
(C) Concentrations of liver and plasma triglycerides in the mice transduced with control (filled box) or RNAi (open box) adenoviruses. Plasma
triglyceride concentrations were measured before (chow) or after (HF) two days of high-fat feeding as indicated. *: p  0.03; **: p  0.0002.
(D) Concentrations of total and HDL/non-HDL plasma cholesterol in the mice transduced with control (filled box) or RNAi (open box) adenovir-
uses. HDL cholesterol was measured in animals after two days of high-fat feeding. Non-HDL cholesterol was calculated by subtracting HDL
from total cholesterol. *: p  0.03; **: p  0.02.
(E) Coordination of lipid synthesis and lipoprotein secretion through transcriptional coactivation by PGC-1. PGC-1 stimulates hepatic lipid
synthesis by coactivating the SREBP family of transcription factors. PGC-1 also promotes lipoprotein secretion through its coactivation of
transcription factors including LXR.
of LXR target genes, such as SREBP1c, is not affected Surprisingly, the mRNA level of LDLR is also reduced by
approximately 40% in response to PGC-1 knockdown,by PGC-1 knockdown (Figure 6H), perhaps reflecting
the observation that PGC-1 is also capable of coacti- suggesting that this coactivator may be a limiting factor,
directly or indirectly, for optimal expression of LDLR invating LXR and stimulating the expression of its targets
(Figure 5). the liver. These data clearly illustrate that PGC-1 is
indeed necessary for the full activation of the lipogenicTo examinewhether PGC-1 is required for the activa-
tion of lipogenic gene expression in vivo, especially in program by the SREBPs and perhaps other as yet unde-
fined transcription factors in the mouse liver.the context of high-fat feeding, we transducedmicewith
Ad-RNAi directed against PGC-1 or a control random Consistent with a key role of PGC-1 in the regulation
of lipoprotein synthesis and secretion, plasma triglycer-RNAi for four days and then switched animals to a high-
fat diet for two days. As expected, the Ad-RNAi directed ide concentration is significantly reduced (15%) in Ad-
RNAi-transduced mice when fed either chow or a high-against PGC-1 greatly reduced endogenous PGC-1
protein in the liver (Figure 7A). Analysis of hepatic gene fat diet (Figure 7C). Hepatic triglyceride levels tend to
be higher in the RNAi group, but the difference doesexpression indicates that the mRNA level of several key
lipogenic enzymes, including FAS, SCD-1, and HMG- not reach statistical significance. As expected, plasma
cholesterol level is increased in mice following high-fatCoA reductase, is significantly decreased in the liver
from mice receiving Ad-RNAi compared to the control feeding (Figure 7D). Somewhat surprisingly, total plasma
cholesterol concentration is slightly but significantlyRNAi vector (Figure 7B). The expression of CYP7a1,
PLTP, and PGC-1 is similar between the two groups. higher in Ad-RNAi-transduced mice following high fat
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feeding. This is due to an increase in both HDL and non- a significant decrease in the expression of mRNA for
the LDLR (Figure 7B). These data suggest that PGC-1HDL cholesterol (Figure 7D). This could be due, at least
is indeed involved in control of the LDLR promoter andin part, to the decreased expression of LDLR observed
that suppression of hepatic LDLR expression may playwhen PGC-1 is knocked down in live animals (Figure
an important role in the elevation of blood cholesterol7B).
in RNAi-treated mice.
Perhaps the most interesting observation from theseDiscussion
in vivo studies is that PGC-1 highly induces the lipo-
genic genes targeted by SREBPs, but the induction ofPGC-1 and PGC-1 have similar effects on mitochon-
these genes does not lead to lipid accumulation in thedrial biogenesis and respiration, but the range of biologi-
liver. Indeed, lipid levels in the liver are actually de-cal functions of PGC-1 is largely unexplored. However,
creased while plasma triglyceride and cholesterol levelsit is already clear that the expressionof PGC-1 is appar-
are significantly elevated. The ability of PGC-1 to alterently controlled by distinct physiological and cellular
the balance between hepatic versus plasma lipids issignals. For example, the expression of PGC-1, but not
extremely robust andclearly indicates that PGC-1mustPGC-1, is strongly increased during differentiation of
be activating additional pathways linked to lipoproteinboth brown and white adipocytes (Kamei et al., 2003;
synthesis and secretion. In fact, the effects of PGC-1Lin et al., 2002a). In contrast, PGC-1 is highly inducible
on plasma triglycerides are very reminiscent of whatin brown fat in response to cold temperature, while PGC-
has been observed with administration of synthetic LXR1 is not (Lin et al., 2002a; Puigserver et al., 1998). In
agonist to animals (Grefhorst et al., 2002; Schultz etthis paper, we have identified a novel mode of regulation
al., 2000).and function for PGC-1, working through transcription
Several pieces of data link PGC-1with the LXR path-factors in the SREBP and LXR families.
way. PGC-1 coactivates LXR on both a synthetic re-First, PGC-1 strongly coactivates the entire SREBP
porter containing multimerized binding elements and anfamily of transcription factors in reporter gene assays.
endogenous promoter (ABCA1) and does so in an LXRImportantly, the effect of PGC-1 on the SREBPs is not
ligand-dependent manner (Figure 5). More importantly,restricted to isolated promoters; PGC-1 also strongly
PGC-1 is recruited to the promoter region of CYP7a1induces the expression of SREBP target genes in rat
and ABCA1 and activates the expression of these LXRliver when ectopically expressed via adenoviral vectors.
target genes. Although studies in this field have notThese include targets of both SREBP1c and SREBP2,
elucidated how LXR activates the pathways of lipidnamely enzymes of fatty acid, triglyceride synthesis, and
transport and VLDL secretion in hepatocytes, the abilitycholesterol biosynthesis. In addition, PGC-1 appears
of PGC-1 to modulate LXR target gene expression into be required for full transcriptional activity of the
cultured cells and in vivo suggests that PGC-1 elicitsSREBPs, as shown by analysis of the FAS promoter
at least a proportion of this hyperlipidemia through co-using PGC-1 RNAi vectors, as well as for the induction
activation of LXR. However, since most of the data pre-of endogenous lipogenic targets in cells and in vivo. The
sented here relating to LXR are essentially correlative,
ability of PGC-1 to augment the stimulatory effects of
it is entirely possible that the effects of PGC-1 on lipo-
SREBP on the FAS promoter appears to be mediated
protein formation and secretion also involve coactiva-
through direct association between PGC-1 and the
tion of other transcription factors. Taken together, it is
SREBPs. Interestingly, SREBP1c docks on PGC-1 at clear that PGC-1 couples these two important aspects
a domain that has no counterpart in PGC-1, and hence, of lipidmetabolism in liver, i.e., lipid synthesis via coacti-
PGC-1 does not coactivate the SREBPs. vation of the SREBPs and lipoprotein secretion via co-
While the effects of adenoviral vectors expressing activation of LXR and likely other transcription factors
PGC-1 and RNAi against PGC-1 substantially mirror (Figure 7E).
each other’s effects on plasma triglycerides, the effects The expression of PGC-1 is highly inducible in re-
of these agents on blood cholesterol appear somewhat sponse to the dietary intake of saturated fats in vivo and
paradoxical. The viral-mediated elevation of PGC-1 by fatty acids in cultured hepatocytes. Notably, many
from the baseline levels seen in chow-fed animals stimu- enzymes involved in cholesterol biosynthesis, such as
lates the elevation of VLDL cholesterol and total choles- HMG-CoA reductase, a rate-limiting enzyme in this path-
terol, but the RNAi against PGC-1, which knocked way and a target for cholesterol-lowering drugs, are all
down the level of this coactivator to undetectable levels, significantly induced by dietary intake of saturated fats.
also raised both HDL and non-HDL cholesterol. Al- The stimulation of this pathway is striking in light of
though a role for PGC-1 acting in a manner indepen- the fact that saturated fats have been known to cause
dent of coactivation of the SREBPs cannot be ruled out, increased atherogenic LDL cholesterol andan increased
this role seems rather unlikely since knockdown of PGC- risk for the development of cardiovascular disease. In
1 caused no change in the expression of PGC-1 (Fig- fact, as shown in Figure 3, adenoviral-mediated expres-
ure 7B). A much more plausible molecular explanation sion of PGC-1 in rat liver activates the programs of de
for these results can be gleaned from the effects of novo lipid synthesis that bears close resemblance to
these agents on the expression of the LDLR. This recep- the effects of dietary saturated fats. More importantly,
tor, which is largely responsible for removal of LDL cho- PGC-1expression leads to accumulation of cholesterol
lesterol from the blood, is not increased at all whenPGC- in VLDL, the precursor to LDL cholesterol. While rodents
1 levels are raised above baseline levels by adenoviral do not accumulate much LDL cholesterol because of
vectors (Figure 3C). In contrast, the near total suppres- its high rate of turnover, this pathway is basically similar
to that in humans, and LDL cholesterol does build upsion of PGC-1 levels by the RNAi (Figure 7A) causes
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calculated after normalization to 18S ribosomal RNA. For hybridiza-in mice when the LDL receptor is mutated. Hence, these
tion, 20 g of total RNA was resolved on a formaldehyde gel, trans-findings strongly suggest that the induction of PGC-1
ferred to nylon membrane, and hybridized with 32P-labeled gene-may be a key step linking the dietary intake of saturated
specific probes. Hybridization to ribosomal protein 36B4 was in-
and trans fats with the elevation of circulating triglycer- cluded as loading control. Data represent mean 
 SEM.
ides and cholesterol.
It is now clear that dietary intake of saturated and Transient Transfection
Mouse H2.35 hepatoma cells (CRL-1995, ATCC) were maintainedtrans fats are crucial in the elevation of LDL cholesterol
in DMEM supplemented with 4% fetal bovine serum in the presencein humans, and the molecular pathways at work here
of 0.2 M dexamethasone. Transient transfection was performedwere previously quite obscure. What is not obscure is
using Superfect (Qiagen). In a typical experiment, 100 ng of reporterthe fact that the resulting increase in cholesterol levels
plasmids were mixed with 20–50 ng of expression constructs for
by these fats has disastrous consequences for public transcription factors in the presence or absence of 0.5–1.0 g of
health: the atherogenic effects of diets rich in saturated PGC-1 expression or RNAi constructs. Equal amounts of DNA were
used for all transfection combinations by adding appropriate vectorand trans fats are now well documented. The role of
DNA. For LXR agonist treatments, T0901317 (Cayman Chemical)PGC-1 as both a target of saturated and trans fatty
was added to a final concentration of 10 M 20 hr before luciferaseacids and as a regulator of VLDL secretion is clearly
assay. All transfection experiments were repeated at least threeillustrated in our studies. Modulation of PGC-1 expres-
times in triplicates. Data represent mean 
 SEM.
sion and activity in liver may provide an important thera-
peutic target for minimizing the deleterious effects of Chromatin Immunoprecipitation
saturated and trans fats on the pathogenesis of athero- H2.35 hepatoma cells were infected with Ad-GFP, Ad-flag-PGC-1,
or Ad-PGC-1 in the absence or presence of Ad-SREBP1c forgenic hyperlipidemia.
2 days. Cells were harvested following brief fixation with 10% forma-
lin for preparation of sheared chromatin. Immunoprecipitation wasExperimental Procedures
performed using anti-flag or IgG control antibodies. The precipitates
were reverse crosslinked for DNA isolation and PCR analysis.High-Fat Feeding and Microarray Analysis
Animalswere fed a standard rodent chow and housed in a controlled
environment with 12 hr light and dark cycles. For high-fat feeding, Protein Interaction Assays
Physical association of PGC-1 andSREBP1c in cells was examinedthree-month-old male C57/Bl6J mice were switched to a diet con-
taining 58% fat-derived calorie (D12331, Research Diets) for 24 or by coimmunoprecipitation. Briefly, H2.35 hepatoma cells were in-
fected with Ad-SREBP1c, Ad-Flag-PGC-1, Ad-Flag-PGC-1 alone48 hr. For high-cholesterol feeding, two groups of mice were fed a
base diet supplemented with either 0.07% or 2% cholesterol for 24 or in combinations as indicated. Nuclei were isolated from infected
cells 48 hr following infection and extracted in a lysis buffer con-or 48 hr. Liver was dissected and immediately frozen for RNA isola-
tion. Affymetrix array hybridization and scanning were performed taining 20 mM HEPES (pH 7.9), 400 mM NaCl, 1.5 mM MgCl2, 0.5
mMDTT, 0.2mMEDTA, 15%glycerol, and 1mMPMSF. Immunopre-by the Core Facility at Dana-Farber Cancer Institute using Murine
430 2.0 chips. Array data were analyzed with d-CHIP software (Li cipitation was performed in the lysis buffer supplemented with 1.5%
Triton X-100 and 0.2 mg/ml BSA using polyclonal antibodies againstand Wong, 2001).
SREBP1 (sc-8984, Santa Cruz Biotechnology). PGC-1s in the com-
plex were revealed by immunoblotting using a monoclonal antibodyFree Fatty Acid Treatments
against the Flag epitope (M2, Sigma). In vitro interaction assaysPrimary hepatocytes were isolated as previously described (Lin et
were performed as previously described (Lin et al., 2002a).al., 2004). Free fatty acids were dissolved in ethanol as 100 mM
stock solutions for further dilution in DMEM supplemented with
0.5% BSA to a final concentration of 400 M. Hepatocytes were PGC-1 RNAi Vectors
treated for 4 hr before RNA isolation and analysis. The RNAi constructs for PGC-1 were generated using two se-
quences in the coding region of PGC-1: 5-GATATCCTCTGTGAT
GTTA-3 (RNAi #1) and 5-GTACGGAACTGCATAAGCA-3 (RNAi #2).Adenoviral Transduction
Male Wistar rats (Charles River Laboratories) were fed a high-fat Oligonucleotides containing these sequences were subcloned into
the pSUPER-retro vector (Brummelkamp et al., 2002). For transientdiet (TD96001, Harlan Taklad) for ten weeks. Animals were anesthe-
tized with Nembutal and transduced with purified adenoviruses via transfection, 1.0 g of pSUPER vector or PGC-1 RNAi constructs
were used in combination with 100 ng of reporter plasmids and 50tail vein injection (1 	 1012 viral particles per rat). Liver toxicity was
monitored by plasma alanine aminotransferase and aspartate ami- ng of expression constructs for appropriate transcription factors.
PGC-1 RNAi adenoviruses were generated using the expressionnotransferase levels as determined by ALT/AST assay kit (505-OP,
Sigma). Plasma and liver were harvested six days following adenovi- cassettes derived from the pSUPER vectors. For knockdown experi-
ments, H2.35 hepatoma cells were infected with either Ad-GFP orral transduction for gene expression and lipid analysis.
Ad-PGC-1 RNAi adenoviruses for 48 hr before incubation with
Ad-SREBP1c. Total RNA were harvested from infected cells 20 hrAnalysis of Liver and Plasma Lipids
following Ad-SREBP1c infection and analyzed by real-time PCR.Liver triglycerides were extracted using chloroform/methanol (2:1)
Adenoviral transduction in mice was performed by tail vein injec-mix, dried in fume hood overnight, and dissolved in a solution con-
tion at 1.5 	 1011 viral particles per mouse (three-month-old C57Bl/taining 60% butanol and 40% of the Triton-X114/methanol mix (2:1).
6 males). After four days, the animals were switched to a high-fatLiver and plasma triglyceride concentrations were measured using
diet for two more days. Plasma samples were collected before anda colorimetric assay kit (337, Sigma). Total plasma cholesterol was
after high-fat feeding and assayed for triglyceride and cholesteroldetermined using the Infinity cholesterol reagent (401, Sigma). For
concentrations. HDL cholesterol was measured using an automatedlipoprotein analysis, 300 l of plasma was fractionated by FPLC.
ACE Clinical Chemistry System (ALFA Wassermann, New Jersey).Concentrations of triglycerides and cholesterol in each fractionwere
Liver was dissected at the end of high-fat feeding for gene expres-determined as described above. Data represent mean 
 SEM.
sion and lipid analysis.
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